Patents by Inventor Marco Bestagno

Marco Bestagno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified effector cell (or chimeric receptor) for treating disialoganglioside G-expressing neoplasia
    Patent number: 10647997
    Abstract: A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-? chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-? chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: May 12, 2020
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Massimo Dominici, Sara Caldrer, Maria Carlotta Spano, Paolo Paolucci, Marco Bestagno, Dario Campana
  • Modified Effector Cell (or Chimeric Receptor) for Treating Disialoganglioside GD2-Expressing Neoplasia
    Publication number: 20140302608
    Abstract: A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-? chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-? chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
    Type: Application
    Filed: October 25, 2012
    Publication date: October 9, 2014
    Inventors: Massimo Dominici, Sara Caldrer, Maria Carlotta Spano, Paolo Paolucci, Marco Bestagno, Dario Campana
  • Monoclonal antibody neutralising cathepsin b activity and uses thereof
    Publication number: 20050260207
    Abstract: The present invention relates to a monoclonal antibody capable of neutralising cathepsin B. In particular, the present invention is concerned with the use of such an antibody for the detection or treatment of diseases associated with an over-expression and/or excessive activity of cathepsin B, such as cancer or arthritis.
    Type: Application
    Filed: April 2, 2002
    Publication date: November 24, 2005
    Inventors: Janko Kos, Ales Premzl, Natasa Kopitar Jerala, Xiaohui Fan, Vito Turk, Marco Bestagno, Oscar Burrone